Meeting
2021 Genitourinary Cancers Symposium
The effect of maximum tumor diameter on disease control in intermediate and high-risk prostate cancer patients treated with brachytherapy boost.
Authors
Matthew Parsons
University of Utah, Salt Lake City, UT
Matthew Parsons , Ryan Hutten , Ashley Khouri , Alexander Tward , Glen Morrell , John Stuart Peterson , Donald Maurice Cannon , Shane Lloyd , Skyler B Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Localized Disease
Track
Prostate Cancer - Localized
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 252)
DOI
10.1200/JCO.2021.39.6_suppl.252
Abstract #
252
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
The importance of the need for better systemic therapy in the definitive treatment of high-risk prostate cancer regardless of whether the initial treatment modality was external beam radiation, I-125 brachytherapy, or radical prostatectomy.
First Author: Jay P. Ciezki
Poster
2014 Genitourinary Cancers Symposium
Novel dosimetric criteria for salvage permanent brachytherapy based on 3D-cancer mapping.
First Author: Koji Okihara
Poster
2024 ASCO Genitourinary Cancers Symposium
Long-term outcomes for patients with radiorecurrent prostate cancer treated with salvage combination IMRT and brachytherapy.
First Author: Michael J. Dattoli
Poster
2023 ASCO Genitourinary Cancers Symposium
Results of a multicenter, randomized, phase 3 trial of trimodality therapy with I-125 brachytherapy, external beam radiation therapy, and long- versus short-term androgen deprivation therapy for localized high-risk prostate cancer (TRIP/TRIGU0907).
First Author: Atsunori Yorozu